Now is the time to reflect on and apply what we’ve learned during the pandemic to make clinical trials better today and tomorrow.
“Everything we do in clinical trials is based on statistical principles, and you have to be comfortable with them.” What do looming ICH E9 changes mean for you and your clinical trials?
H1’s Director of Product Marketing, Alexandra Moens, discusses the importance of promoting diversity and how it applies to clinical trials, why the time is now for companies to take action steps to ensure a more diverse patient population, and how H1 is uniquely positioned to help companies harness existing data to significantly enhance their diversity efforts.
60% of clinical researchers surveyed say their organizations are slower to adopt innovations than their peers.
Learn about a new collaborative effort to pilot a network of sustainable, connected, community-based clinical trial sites in the U.S.